Genmab’s bispecific halves risk of death in first-line HNSCC
Genmab’s petosemtamab, an investigational IgG1-bispecific antibody, plus Keytruda (pembrolizumab) reduced the risk of death by 50% in a Phase III…
Oncology
-
-
Podcast: ESMO26: Major readouts from the 2026 congress
This year's European Society of Medical Oncology (ESMO) Congress has come to a close, with hundreds of studies having been…
-
ESMO26: US and FDA movements to improve oncology trials a positive signal
Since the Trump Administration took office in the White House, there has been an uptick in the number of guidance…
-
ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine
Arguably the most impactful readout in skin cancer in recent months was MSD and Moderna’s melanoma cancer vaccine data. At…
-
ESMO26: The “paradigm-shifting” readouts in endometrial & ovarian cancer
At this year’s European Society for Medical Oncology (ESMO) Congress, attention has shifted toward indications that have traditionally received less…
-
ESMO26: Sac-TMT’s OptiTROP-Lung04 survival gain holds, putting the onus on MSD
On 25 October 2026, Professor Wenfeng Fang presented the final overall survival (OS) analysis of the Phase III OptiTROP-Lung04 trial…
-
ESMO26: Combination therapies show promise in prostate cancer
Prostate cancer is the most diagnosed cancer in men worldwide, but little is known about why some cancers are slow-growing,…
-
ESMO26: Novel combo successes signal shift from frontline chemo in cold cancers
The past few years have seen a number of revolutionary modalities join the oncology landscape, such as antibody-drug conjugates (ADCs),…
-
ESMO26: Amgen’s Imdelltra posts win in first-line SCLC maintenance setting
On 24 October, 2026, Jacob Sands of Dana-Farber Cancer Institute presented the primary analysis of the Phase III DeLLphi-305 trial…
-
ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer
In 2023, Bristol Myers Squibb entered an $8.4bn licensing agreement with Chinese biotech SystImmune for izalontamab brengitecan, or iza-bren, an…
